Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Formycon AG
  6. Summary
    FYB   DE000A1EWVY8

FORMYCON AG

(FYB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
06/16/2021 06/17/2021 06/18/2021 06/21/2021 06/22/2021 Date
61.7(c) 60.4(c) 61(c) 59.1(c) 59.2 Last
10 755 9 323 6 388 8 210 4 201 Volume
-0.80% -2.11% +0.99% -3.11% +0.17% Change
More quotes
Estimated financial data (e)
Sales 2021 43,3 M 51,5 M 51,5 M
Net income 2021 -10,1 M -12,0 M -12,0 M
Net cash position 2021 33,1 M 39,4 M 39,4 M
P/E ratio 2021 -67,4x
Yield 2021 -
Sales 2022 60,0 M 71,5 M 71,5 M
Net income 2022 7,00 M 8,33 M 8,33 M
Net cash position 2022 29,7 M 35,4 M 35,4 M
P/E ratio 2022 138x
Yield 2022 -
Capitalization 650 M 774 M 774 M
EV / Sales 2021 14,3x
EV / Sales 2022 10,3x
Nbr of Employees 117
Free-Float 61,2%
More Financials
Company
Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development... 
More about the company
Ratings of Formycon AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about FORMYCON AG
05/20ORIGINAL-RESEARCHá : Formycon AG (von First Berlin Equity Research GmbH): Kaufen
DJ
05/17PRESS RELEASEá : Formycon Publishes Annual Financial Statements for the 2020 Fin..
DJ
05/17FORMYCONá : Publishes Annual Financial Statements for the 2020 Financial Year
EQ
04/27FORMYCONá : receives approval for early action for COVID-19 drug FYB207 as part ..
PU
04/27FORMYCONá : receives approval for early action for COVID-19 drug FYB207 as part ..
EQ
04/27PRESS RELEASEá : Formycon receives approval for early action for COVID-19 drug F..
DJ
03/26ORIGINAL-RESEARCHá : Formycon AG (von First Berlin Equity Research GmbH): Hinzuf..
DJ
03/25FORMYCONá : COVID-19 Drug FYB207 even more efficient against SARS-CoV-2 Mutant B..
PU
03/25FORMYCONá : COVID-19 Drug FYB207 even more efficient against SARS-CoV-2 Mutant B..
EQ
03/25PRESS RELEASEá : Formycon's COVID-19 Drug FYB207 even more efficient against SAR..
DJ
03/24FORMYCONá : and Leukocare cooperate in the development of high-quality biopharma..
PU
03/24FORMYCONá : and Leukocare cooperate in the development of high-quality biopharma..
EQ
03/24PRESS RELEASEá : Formycon and Leukocare cooperate in the development of high-qua..
DJ
03/05FORMYCON AGá : Notification and public disclosure of transactions by persons
EQ
03/01FORMYCONá : confirms BLA-Submission Strategy and Timeline for its Lucentis(R)* B..
PU
More news
News in other languages on FORMYCON AG
06/09ORIGINAL-RESEARCH : GBC Insider Focus Index (von GBC AG):
05/20ORIGINAL-RESEARCH : Formycon AG (von First Berlin Equity Research GmbH): Kaufen
05/17DGAP-NEWSá : Formycon gibt Jahresabschluss für das -2-
05/17FORMYCONá : gibt Jahresabschluss für das Geschäftsjahr 2020 bekannt
05/17Formycon gibt Jahresabschluss für das Geschäftsjahr 2020 bekannt
More news
Chart FORMYCON AG
Duration : Period :
Formycon AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FORMYCON AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Last Close Price 59,10 €
Average target price 70,70 €
Spread / Average Target 19,6%
EPS Revisions
Managers and Directors
NameTitle
Carsten Brockmeyer Chief Executive Officer
Nicolas CombÚ Chief Financial Officer
Olaf Stiller Chairman-Supervisory Board
Stefan Glombitza Chief Operating Officer
Peter Wendeln Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
FORMYCON AG11.51%774
MODERNA, INC.99.33%83 614
LONZA GROUP AG13.26%52 103
IQVIA HOLDINGS INC.35.88%46 660
CELLTRION, INC.-24.79%33 793
SEAGEN INC.-9.62%28 728